drugset / Trial / NCT05644600
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
RandomizedCrossoverOpen-labelTreatment
Summary
The study is intended to quantify the effect of co-administration and staggered dosing of AZD5055 and nintedanib on exposures of nintedanib in healthy participants.
Timeline
- Start
- 2023-05-26
- Primary completion
- 2023-07-17
- Completion
- 2023-07-17
Outcome
Outcome not reported
Stopped: “The study was terminated as no drug-drug interactions were observed in Part-A of the study and therefore Part-B of the study was not required as per protocol.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5055 | Unknown | — | Oral |
| Subject | Nintedanib | Small molecule | — | Oral |
Indications
No indication recorded.